David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 2,171 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $29.71, for a total value of $64,500.41. Following the completion of the transaction, the insider directly owned 69,792 shares in the company, valued at approximately $2,073,520.32. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.36, for a total value of $186,377.28.
• On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.58, for a total value of $401,720.48.
• On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $31.33, for a total value of $13,033.28.
• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total value of $175,585.68.
• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.54, for a total value of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total transaction of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.

Mineralys Therapeutics Price Performance

MLYS stock traded down $2.40 during trading hours on Wednesday, reaching $26.86. 1,630,121 shares of the stock were exchanged, compared to its average volume of 1,093,224. The firm’s 50-day moving average is $27.12 and its 200-day moving average is $32.76. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -13.10 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 12 month low of $12.59 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. As a group, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Institutional Trading of Mineralys Therapeutics

Several institutional investors have recently modified their holdings of the business. KBC Group NV bought a new stake in shares of Mineralys Therapeutics in the first quarter worth $33,000. Jennison Associates LLC grew its stake in shares of Mineralys Therapeutics by 0.6% in the first quarter. Jennison Associates LLC now owns 1,266,174 shares of the company’s stock worth $34,301,000 after purchasing an additional 7,521 shares during the last quarter. Candriam S.C.A. grew its stake in shares of Mineralys Therapeutics by 18.2% in the first quarter. Candriam S.C.A. now owns 801,904 shares of the company’s stock worth $21,724,000 after purchasing an additional 123,517 shares during the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Mineralys Therapeutics by 321.2% in the first quarter. Y Intercept Hong Kong Ltd now owns 132,099 shares of the company’s stock worth $3,579,000 after purchasing an additional 100,740 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of Mineralys Therapeutics by 21.3% in the first quarter. Pictet Asset Management Holding SA now owns 1,034,438 shares of the company’s stock worth $28,023,000 after purchasing an additional 181,555 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MLYS shares. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Bank of America upped their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, March 13th. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating for the company. Finally, HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.14.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.